Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection

Diego A. Espinosa, Dennis Christensen, Christian Muñoz, Sanjay Singh, Emily Locke, Peter Andersen, Fidel P Zavala

Research output: Contribution to journalArticle

Abstract

Despite several decades of extensive research, the development of a highly efficacious malaria vaccine has yet to be accomplished. While the RTS,S malaria vaccine candidate shows the potential to prevent a substantial number of clinical malaria cases, significant improvements in protective efficacy are still needed. Multiple studies have shown that RTS,S induces protective antibody and CD4+ T-cell responses, but limited or negligible CD8+ T cells. In this study, we evaluated the immunogenicity and protective capacity of full-length recombinant Plasmodium falciparum circumsporozoite protein administered with the novel cationic liposomal adjuvant system CAF09. Using newly developed transgenic rodent malaria parasites expressing the full-length Plasmodium falciparum circumsporozoite protein, we demonstrate that this liposome-based protein-in-adjuvant formulation is capable of inducing robust antibody and CD8+ T-cell responses that strongly inhibit parasite infection and development of liver stages, conferring durable sterilizing immunity. These findings underscore the potential of liposome-based adjuvants for inducing robust humoral and CD8+ T-cell responses and warrant further studies toward the development of novel subunit vaccine formulations with this adjuvant system.

Original languageEnglish (US)
Article number10
Journalnpj Vaccines
Volume2
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Malaria
Immunity
Rodentia
Malaria Vaccines
T-Lymphocytes
Antibodies
Plasmodium falciparum
Infection
Liposomes
Parasitic Diseases
Subunit Vaccines
Parasites
Liver
Research
Proteins
Protozoan circumsporozoite protein

ASJC Scopus subject areas

  • Pharmacology
  • Infectious Diseases
  • Immunology
  • Pharmacology (medical)

Cite this

Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection. / Espinosa, Diego A.; Christensen, Dennis; Muñoz, Christian; Singh, Sanjay; Locke, Emily; Andersen, Peter; Zavala, Fidel P.

In: npj Vaccines, Vol. 2, No. 1, 10, 01.12.2017.

Research output: Contribution to journalArticle

@article{cbca0bd8519e4a39b1bbcd5428ed0565,
title = "Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection",
abstract = "Despite several decades of extensive research, the development of a highly efficacious malaria vaccine has yet to be accomplished. While the RTS,S malaria vaccine candidate shows the potential to prevent a substantial number of clinical malaria cases, significant improvements in protective efficacy are still needed. Multiple studies have shown that RTS,S induces protective antibody and CD4+ T-cell responses, but limited or negligible CD8+ T cells. In this study, we evaluated the immunogenicity and protective capacity of full-length recombinant Plasmodium falciparum circumsporozoite protein administered with the novel cationic liposomal adjuvant system CAF09. Using newly developed transgenic rodent malaria parasites expressing the full-length Plasmodium falciparum circumsporozoite protein, we demonstrate that this liposome-based protein-in-adjuvant formulation is capable of inducing robust antibody and CD8+ T-cell responses that strongly inhibit parasite infection and development of liver stages, conferring durable sterilizing immunity. These findings underscore the potential of liposome-based adjuvants for inducing robust humoral and CD8+ T-cell responses and warrant further studies toward the development of novel subunit vaccine formulations with this adjuvant system.",
author = "Espinosa, {Diego A.} and Dennis Christensen and Christian Mu{\~n}oz and Sanjay Singh and Emily Locke and Peter Andersen and Zavala, {Fidel P}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41541-017-0011-y",
language = "English (US)",
volume = "2",
journal = "npj Vaccines",
issn = "2059-0105",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection

AU - Espinosa, Diego A.

AU - Christensen, Dennis

AU - Muñoz, Christian

AU - Singh, Sanjay

AU - Locke, Emily

AU - Andersen, Peter

AU - Zavala, Fidel P

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Despite several decades of extensive research, the development of a highly efficacious malaria vaccine has yet to be accomplished. While the RTS,S malaria vaccine candidate shows the potential to prevent a substantial number of clinical malaria cases, significant improvements in protective efficacy are still needed. Multiple studies have shown that RTS,S induces protective antibody and CD4+ T-cell responses, but limited or negligible CD8+ T cells. In this study, we evaluated the immunogenicity and protective capacity of full-length recombinant Plasmodium falciparum circumsporozoite protein administered with the novel cationic liposomal adjuvant system CAF09. Using newly developed transgenic rodent malaria parasites expressing the full-length Plasmodium falciparum circumsporozoite protein, we demonstrate that this liposome-based protein-in-adjuvant formulation is capable of inducing robust antibody and CD8+ T-cell responses that strongly inhibit parasite infection and development of liver stages, conferring durable sterilizing immunity. These findings underscore the potential of liposome-based adjuvants for inducing robust humoral and CD8+ T-cell responses and warrant further studies toward the development of novel subunit vaccine formulations with this adjuvant system.

AB - Despite several decades of extensive research, the development of a highly efficacious malaria vaccine has yet to be accomplished. While the RTS,S malaria vaccine candidate shows the potential to prevent a substantial number of clinical malaria cases, significant improvements in protective efficacy are still needed. Multiple studies have shown that RTS,S induces protective antibody and CD4+ T-cell responses, but limited or negligible CD8+ T cells. In this study, we evaluated the immunogenicity and protective capacity of full-length recombinant Plasmodium falciparum circumsporozoite protein administered with the novel cationic liposomal adjuvant system CAF09. Using newly developed transgenic rodent malaria parasites expressing the full-length Plasmodium falciparum circumsporozoite protein, we demonstrate that this liposome-based protein-in-adjuvant formulation is capable of inducing robust antibody and CD8+ T-cell responses that strongly inhibit parasite infection and development of liver stages, conferring durable sterilizing immunity. These findings underscore the potential of liposome-based adjuvants for inducing robust humoral and CD8+ T-cell responses and warrant further studies toward the development of novel subunit vaccine formulations with this adjuvant system.

UR - http://www.scopus.com/inward/record.url?scp=85035200631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035200631&partnerID=8YFLogxK

U2 - 10.1038/s41541-017-0011-y

DO - 10.1038/s41541-017-0011-y

M3 - Article

C2 - 28936360

AN - SCOPUS:85035200631

VL - 2

JO - npj Vaccines

JF - npj Vaccines

SN - 2059-0105

IS - 1

M1 - 10

ER -